# Narration and storyboard draft: Pasteurized Akkermansia and Metabolic Health

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Akkermansia is a promising microbial target, but a genus name is not a product identity. Our review examined 59 relevant original reports. The first human pasteurized MucT trial changed insulin-sensitivity and cholesterol measures, while its original Results reported unchanged fasting glycemia and HbA1c. A larger trial also had a null full-population primary insulin-sensitivity endpoint, with exploratory signals among people with low baseline Akkermansia. Those subgroups deserve prospective testing. There is also a genuine clinical positive: a 2026 randomized MucT trial found less weight regain over 24 weeks after a diet lead-in. We preserve that result as a separately scored supplemental claim, rather than changing our previously registered glycemic/function endpoint after seeing it. The primary grade is Gamma, while the first weight-maintenance result reaches Delta in its specific setting. Other strains and mixtures have their own successes and nulls. A different HB05 product improves selected leg torque, and an Akkermansia-containing mixture has a glucose-control signal; neither proves that all retail products are interchangeable or that Akkermansia alone is necessary. Fiber and diet can improve metabolism while changing several organisms, and some benefits occur without increased Akkermansia. The useful next step is exact-product replication with prespecified clinical outcomes, baseline subgroup interactions and longer safety follow-up.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.